The Audited Consolidated Financial Results for the half and year ended as on 31st March, 2025 of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare Ltd filed its audited consolidated financial results for FY25 (year ended March 31, 2025) after a delay caused by the insolvency proceedings of its wholly-owned subsidiary, Dr. Smiths Biotech Pvt Ltd, which was admitted to CIRP by the NCLT on April 28, 2025. The holding company itself is also under CIRP (NCLT order dated June 11, 2024), with board powers suspended and management vested in Resolution Professional Roshen Chordiya. Total income collapsed by roughly 50% to Rs. 3,106.66 lakhs (from Rs. 6,213.02 lakhs in FY24). The company swung from a small profit of Rs. 14.86 lakhs to a massive net loss of Rs. 2,597.75 lakhs, which includes an exceptional item of Rs. 1,235.37 lakhs. Statutory auditor M/s. S S R C A & Co. issued a Disclaimer of Opinion, citing inability to obtain sufficient audit evidence due to incomplete records, inventory discrepancies, unreconciled balances, and pervasive CIRP-related limitations.
This is a deeply negative filing for shareholders — the auditor refused to give any opinion on the financials, explicitly flagged material uncertainty over the company's ability to continue as a going concern, and the company is operating under insolvency resolution. Investors should expect extreme volatility, likely equity dilution or near-total loss under any resolution plan, and the stock is effectively in distressed territory.